LTZ secures USD 38 million financing to accelerate global first-in-class "myeloid cell engager" immunotherapy pipeline

On May 6, 2026, REDWOOD CITY, Calif., & SHENZHEN, China — LTZ Therapeutics ("LTZ" or the "Company"), a clinical-stage biotechnology company focused on novel immunotherapies, today announced the completion of a USD 38 million financing round. This round was led by GL Ventures. A major international sovereign wealth fund made a substantial follow-on investment. Several existing shareholders also participated, including a global pharmaceutical major, Boyu Growth Ventures, 5Y Capital, Lanchi Ventures, Unicorn Capital Partners, and Shunwei Capital. Since its inception in 2022, LTZ has raised approximately USD 130 million in aggregate.

Leveraging its globally first-in-class proprietary technology platform, U-MCE™ (Universal Myeloid Cell Engager), LTZ will use the proceeds from this financing round to accelerate the development of its Myeloid Cell Engager (MCE) immunotherapy pipeline. In particular, the funding will support the ongoing Phase I clinical study of its lead candidate LTZ-301, targeting oncology and autoimmune diseases, which is actively recruiting subjects at multiple renowned clinical sites across the United States. The funds will also facilitate the Investigational New Drug (IND) application and the initiation of the Phase I clinical study for the Company's second candidate, LTZ-232.

LTZ's R&D strategy deeply integrates "Reverse Translational Science" with a profound understanding of tumor microenvironment biology, particularly myeloid cell biology. Macrophages represent one of the most abundant immune cell populations in the tumor microenvironment across various hematologic malignancies and solid tumors. Therefore, effectively engaging and activating macrophages to subsequently kill tumor cells holds significant therapeutic potential for a broad patient population. LTZ is independently developing its novel U-MCE technology platform, designed to enhance the phagocytic function of macrophages and monocytes under different polarization states, thereby building a broad immunotherapeutic barrier against a wide range of indications in both oncological and non-oncological settings.

LTZ-301 is a novel "Myeloid Cell Engager" bispecific antibody that directs macrophages and monocytes to target and eliminate CD79b-positive B cells, thereby enhancing phagocytosis and efficient clearance of tumor cells. CD79b is a specific tumor antigen receptor highly expressed in B-cell malignancies, including cases that are relapsed or refractory following existing CD19- or CD20-targeted therapies. Currently, LTZ-301 is being evaluated in a Phase I clinical study in the United States, which is actively recruiting patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL) from multiple well-known clinical sites. Preclinical studies have demonstrated that LTZ-301 exhibits potent pharmacological activity in both in vitro and in vivo models, along with a favorable safety profile.